GSK seeks HIV paradigm shift with long-acting injectable
By Whang, byung-woo | translator Alice Kang
24.12.04 05:47:33
가나다라
0
Company applies for reimbursement of Vocabria+Rekambys combo to HIRA in May
Completed pharmacoeconomic evaluation, and is gaining attention on whether it will be presented to the last Drug Reimbursement Evaluation Committee this year
Has the convenience of dosing 6 times a year compared to existing therapies that require daily dosing
With the long-acting HIV drug Vocabria+Rekambys combination therapy seeking insurance reimbursement coverage, attention is being paid to whether the drug’s introduction will bring about a shift in the treatment environment.
▲GSK Korea applied for the reimbursement of the Vocabria+Rekambys combination in May
According to industry sources on the 3rd, GSK Korea has completed pharmacoeconomic evaluations for its new HIV drug combination, Vocabria (cabotegravir)+Rekambys (rilpivirine), and is awaiting review by the National Health Insurance Review and Assessment Service Drug Reimbursement Evaluation Committee.
GSK Korea filed for reimbursement review in May and may be presented as an agenda at the last Drug Reimbursement Evaluation Committee meeting of the year, which
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)